Compare Gilead Sciences, Inc. (GILD) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard International High Dividend Yield ETF — how do they compare? Gilead Sciences, Inc. trades at $151.12 (market cap $182.40B), while Vanguard International High Dividend Yield ETF trades at $100.41 (market cap $22.80B). The key difference: Gilead Sciences, Inc. is far larger — about 8× Vanguard International High Dividend Yield ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| GILD | VYMI | |
|---|---|---|
Market Cap | $182.40B | $22.80B |
Volume | 4,469,821 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $107.13 |
52-Week Low | $116.74 | $82.92 |
Typical Hold Time | 111 Days | 50 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
VYMI trades at $100.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. Recent news highlights institutional accumulation and positive performance comparisons to peers. The ETF's international high-dividend strategy focuses on financials, energy, and healthcare sectors.
Outlook remains mixed: bullish sentiment from media and institutional inflows contrasts with bearish technicals. Key opportunities include sector alignment with rising rates and attractive yield; risks involve global economic volatility and concentrated financial exposure. Investors should weigh dividend stability against technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
